Radius Health (RDUS) Trading 6.1% Higher

Radius Health Inc (NASDAQ:RDUS) traded up 6.1% during mid-day trading on Tuesday . The company traded as high as $20.90 and last traded at $20.79. 536,730 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 592,390 shares. The stock had previously closed at $19.60.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Monday, May 6th. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. HC Wainwright reaffirmed a “hold” rating on shares of Radius Health in a research report on Thursday, May 9th. Cowen reaffirmed a “hold” rating on shares of Radius Health in a research report on Wednesday, May 8th. Finally, ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $38.00.

The company has a current ratio of 5.16, a quick ratio of 5.04 and a debt-to-equity ratio of 6.75. The stock has a market capitalization of $958.57 million, a P/E ratio of -4.26 and a beta of 0.98.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.32. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The firm had revenue of $34.42 million during the quarter, compared to analysts’ expectations of $33.99 million. As a group, analysts predict that Radius Health Inc will post -3.51 EPS for the current year.

In other Radius Health news, Director Jessica Hopfield purchased 12,800 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average cost of $19.23 per share, with a total value of $246,144.00. Following the transaction, the director now directly owns 12,800 shares in the company, valued at approximately $246,144. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Joseph Francis Kelly purchased 2,000 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were acquired at an average cost of $21.43 per share, with a total value of $42,860.00. Following the completion of the transaction, the vice president now owns 5,000 shares in the company, valued at $107,150. The disclosure for this purchase can be found here. Company insiders own 4.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlueMountain Capital Management LLC purchased a new position in Radius Health during the 1st quarter valued at about $671,000. Man Group plc lifted its position in Radius Health by 12.3% during the 1st quarter. Man Group plc now owns 451,012 shares of the biopharmaceutical company’s stock valued at $8,994,000 after acquiring an additional 49,250 shares during the period. Oxford Asset Management LLP purchased a new position in Radius Health during the 1st quarter valued at about $873,000. Ellington Management Group LLC purchased a new position in Radius Health during the 1st quarter valued at about $203,000. Finally, Wellington Management Group LLP lifted its position in Radius Health by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 3,859,878 shares of the biopharmaceutical company’s stock valued at $76,966,000 after acquiring an additional 270,676 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Radius Health (RDUS) Trading 6.1% Higher” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2019/05/21/radius-health-rdus-trading-6-1-higher.html.

Radius Health Company Profile (NASDAQ:RDUS)

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Read More: Buy-Side Analysts

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit